Durata Therapeutics (DRTX) Closes 8.63M IPO at $9/Share
Tweet Send to a Friend
Durata Therapeutics (Nasdaq: DRTX) today announced the closing of its initial public offering of 8,625,000 shares of common stock at a public offering price of $9.00 per share, before underwriting discounts, including 1,125,000 shares of common stock issued upon the exercise in full by the underwriters of their option to purchase additional shares at the public offering price, less the underwriting discount.
BofA Merrill Lynch and Credit Suisse Securities (USA) LLC acted as joint book-running managers for the offering. RBC Capital Markets, LLC and Wedbush PacGrow Life Sciences acted as the co-managers for the offering.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
BofA Merrill Lynch and Credit Suisse Securities (USA) LLC acted as joint book-running managers for the offering. RBC Capital Markets, LLC and Wedbush PacGrow Life Sciences acted as the co-managers for the offering.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- UPDATE: Google (GOOG) Improves Maps for Mobile
- U.S. SEC Appoints Lona Nallengara as Chief of Staff; Keith Higgins as Corp. Finance Director
- Morgans Hotel Group (MHGC) Clarifies Yucaipa Statements
Create E-mail Alert Related Categories
Corporate News, IPOsRelated Entities
Credit Suisse, Merrill Lynch, Bank of America, RBC Capital
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
